secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001193125-22-282059
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ikena Oncology reports initial IK-175 clinical data: 20% ORR in combination with nivolumab in urothelial carcinoma
--------------------------------------------------------------------------------

- IK-175 combo with nivolumab: 20% ORR, 40% DCR in heavily pretreated urothelial carcinoma patients who progressed on checkpoint inhibitors.
- Monotherapy: 10% ORR, 20% DCR; one confirmed partial response with duration of response 14.9 months and ongoing.
- Dose escalation in solid tumors: prolonged stable disease up to >19 months; MTD not reached; 1200mg selected as expansion dose.
- Well tolerated with low-grade rash, nausea (monotherapy) and fatigue, dysgeusia (combo); only 2 serious adverse events.
- Program in collaboration with Bristol Myers Squibb; opt-in decision eligible through early 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312522282059/0001193125-22-282059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312522282059/d410137d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-282059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer